A neutral, evidence-rated side-by-side of Semaglutide and Tirzepatide. Figures are typical reference values, not recommendations.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Type | Peptide | Peptide |
| Evidence level | Well established | Well established |
| Primary class | Injectable | Injectable |
| Half-life | ~7 days | ~5 days |
| Typical dose | 1–2.4 mg/wk | 5–10 mg/wk |
| Documented effects | 3 | 4 |
| Documented side effects | 2 | 4 |
A once-weekly GLP-1 receptor agonist licensed for type 2 diabetes and obesity — the drug that defined the current weight-loss era. Large, well-evidenced weight loss with a gastrointestinal side-effect profile as the main limit.
Full Semaglutide page →A once-weekly dual GIP/GLP-1 receptor agonist licensed for type 2 diabetes and obesity. Produces the largest mean weight loss of any approved agent to date, at the cost of a dose-limiting gastrointestinal side-effect profile.
Full Tirzepatide page →